Overview of Dr. Hassoun
Dr. Hani Hassoun is a hematologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Pierre and Marie Curie University and has been in practice 34 years. Dr. Hassoun accepts several types of health insurance, listed below. He is one of 61 doctors at Memorial Sloan Kettering Cancer Center who specialize in Hematology. He also speaks multiple languages, including French. He has more than 100 publications and over 500 citings.
Office
1275 York Ave
New York, NY 10065
Education & Training
- St Elizabeth's Medical CenterFellowship, Hematology and Medical Oncology, 1987 - 1991
- Brigham and Women's HospitalResidency, Internal Medicine, 1983 - 1986
- Pierre and Marie Curie University Class of 1983
Certifications & Licensure
- NY State Medical License 2002 - 2026
- NJ State Medical License 2024 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top Doctors: New York Metro Area Castle Connolly, 2008-2014
Clinical Trials
- Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis Start of enrollment: 2007 Feb 01
- Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma Start of enrollment: 2007 Nov 01
- Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L Start of enrollment: 2008 Dec 10
- Join now to see all
Publications & Presentations
PubMed
- 310 citationsHigh Incidence of Thromboembolic Events in Patients Treated With Cisplatin-Based Chemotherapy: A Large Retrospective AnalysisRussell A. Moore, Nelly G. Adel, Elyn Riedel, Manisha Bhutani, Darren R. Feldman
Journal of Clinical Oncology. 2011-09-01 - 43 citationsCOVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers.Malin Hultcrantz, Joshua Richter, Cara A. Rosenbaum, Dhwani Patel, Eric L. Smith
Blood Cancer Discovery. 2020-07-30 - 101 citationsGPRC5D-Targeted CAR T Cells for Myeloma.Sham Mailankody, Sean M Devlin, Jonathan Landa, Karthik Nath, Claudia Diamonte
The New England Journal of Medicine. 2022-09-29
Abstracts/Posters
- Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...Hani Hassoun, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloi...Hani Hassoun, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloi...Hani Hassoun, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Other Languages
- French
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPOHumana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: